Published in Drugs Today (Barc) on October 01, 2011
THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics (2012) 1.44
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology (2013) 0.92
THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms. Ann Transl Med (2014) 0.75
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging (2007) 1.72
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet (2005) 1.63
Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med (1998) 1.58
Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol (1999) 1.51
Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med (1998) 1.43
The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients. J Pharm Pharm Sci (2000) 1.43
Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging (2015) 1.41
Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res (2008) 1.27
Digital X-ray radiogrammetry combined with semiautomated analysis of joint space widths as a new diagnostic approach in rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Rheum (2005) 1.18
Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg (2000) 1.14
[Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie (2010) 1.14
Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging (2010) 1.11
Gastric cancer in very young adults: apropos four patients and a review of the literature. J Cancer Res Clin Oncol (2000) 1.11
Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. Eur Radiol (2003) 1.09
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie (2010) 1.06
Cognitive predictors of adherence to malaria prophylaxis regimens on return from a malarious region: a prospective study. Soc Sci Med (1999) 1.05
Malaria prophylaxis and the media. Lancet (1996) 1.05
Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol (2003) 1.04
Characterization of the Bacillus subtilis spore morphogenetic coat protein CotO. J Bacteriol (2005) 1.02
Peripheral bone status in rheumatoid arthritis evaluated by digital X-ray radiogrammetry and compared with multisite quantitative ultrasound. Calcif Tissue Int (2006) 1.00
Human thyroglobulin autoantibodies of subclasses IgG2 and IgG4 bind to different epitopes on thyroglobulin. Immunology (1989) 0.99
Conjoined lumbosacral nerve roots: current aspects of diagnosis. Eur Spine J (2003) 0.95
Induction of benign symmetric lipomatosis (Launois-Bensaude syndrome) in a female patient after liver transplantation. Dermatology (2008) 0.94
Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm (2001) 0.94
Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT. Rheumatol Int (2005) 0.92
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie (2011) 0.91
Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med (1998) 0.88
Musculoskeletal support of lumbar spine stability. Pathophysiology (2005) 0.88
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology (2009) 0.88
Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5. Clin Nephrol (2008) 0.88
[Extraosseous nuclide uptake during skeletal scintigraphy. Heparin-calcium-induced 99mTc-HMDP accumulation]. Rofo (1985) 0.88
Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol (1999) 0.88
Resistance of macrophages to the suppressive effect of interleukin-10 following thermal injury. Am J Physiol Cell Physiol (2001) 0.87
Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology (2004) 0.85
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging (2011) 0.85
Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun (1998) 0.84
Molecular cloning, gene organization and expression of rainbow trout (Oncorhynchus mykiss) inducible nitric oxide synthase (iNOS) gene. Biochem J (2001) 0.84
[Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment]. Pathologe (2005) 0.83
Rat retinal pigment epithelial cells express an inducible form of nitric oxide synthase and produce nitric oxide in response to inflammatory cytokines and activated T cells. Immunology (1994) 0.82
Tumor markers, liver function tests and symptoms in 115 patients with isolated colorectal liver metastases. Int J Biol Markers (1989) 0.82
The impact of technical conditions of X-ray imaging on reproducibility and precision of digital computer-assisted X-ray radiogrammetry (DXR). Skeletal Radiol (2004) 0.81
Self-reported eye symptoms and related diagnostic findings--comparison of risk factor profiles. Indoor Air (2005) 0.81
CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. J Immunol (1996) 0.81
Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med (2000) 0.81
Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci (2002) 0.81
Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res (1999) 0.81
Congenital microgastria, growth hormone deficiency and diabetes insipidus. Eur J Pediatr (1997) 0.81
Direct labeling of monoclonal antibodies with technetium-99m by photoactivation. J Nucl Med (1995) 0.80
131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experience. Eur J Pediatr (1987) 0.80
Late results of heterotopic autotransplantation of splenic tissue into the greater omentum. World J Surg (1998) 0.80
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother (1998) 0.80
Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin (1998) 0.79
Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients. Nucl Med Commun (1997) 0.79
Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol (2005) 0.79
[Significance of multiple organ failure for the prognosis of surgical intensive care patients]. Dtsch Med Wochenschr (2006) 0.79
Semiquantitative SPECT tumor uptake of technetium-99m-labeled anti-CEA monoclonal antibody in colorectal tumor. J Nucl Med (1995) 0.79
Gated metabolic positron emission tomography (GAPET) of the myocardium: 18F-FDG-PET to optimize recognition of myocardial hibernation. Nucl Med Commun (1998) 0.78
Tumour imaging of bladder carcinomas and their metastases with 111indium-labelled monoclonal anti-CEA antibody BW 431/26. Br J Cancer Suppl (1990) 0.78
Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc) (2012) 0.78
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation. J Nucl Med (1996) 0.78
[Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system]. Pneumologie (2012) 0.78
Is technetium-99 m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis? Int J Card Imaging (1990) 0.78
Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging (2010) 0.77
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc (2012) 0.77
[Influence of body constitution on bone mineral density measured by digital radiogrammetry]. Rofo (2005) 0.77
Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma (1999) 0.77
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res (2013) 0.77
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results. Nucl Med Commun (1998) 0.77
Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging. Bioorg Med Chem (2007) 0.77
[Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET]. Nuklearmedizin (1998) 0.76
Multi-site quantitative ultrasound compared to dual energy X-ray absorptiometry in rheumatoid arthritis: effects of body mass index and inflamed soft tissue on reproducibility. Rheumatol Int (2006) 0.76
Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant (2001) 0.76
Nitric oxide production by human proximal tubular cells: a novel immunomodulatory mechanism? Kidney Int (1994) 0.76
Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril (1991) 0.76
Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transpl Infect Dis (2007) 0.76
[Clinical trial for differentiation between corticoid-induced osteoporosis and periarticular demineralization via digital radiogrammetry in patients suffering from rheumatoid arthritis]. Z Rheumatol (2004) 0.75
Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun (1997) 0.75
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm. Clin Exp Metastasis (2014) 0.75
Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA. Br J Cancer Suppl (1990) 0.75
[Immunoscintigraphy in stomach neoplasms with anti-CEA BW 431/26 monoclonal antibodies marked with Tc 99 m]. Rev Med Chil (1991) 0.75
Depressed T cell-derived IFN-gamma following trauma-hemorrhage: a potential mechanism for diminished APC responses. Langenbecks Arch Surg (2007) 0.75
Pancreatic neuroendocrine neoplasms. Minerva Gastroenterol Dietol (2012) 0.75
[Intraoperative localization of metastases with a hand-held gamma probe]. Nuklearmedizin (1995) 0.75
OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma (1997) 0.75
Immunoscintigraphy with 99Tcm-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up. Nucl Med Commun (1999) 0.75
[Gamma-camera functional scintigraphy in the differential diagnosis of Basedow's disease: results in 423 patients]. Rontgenpraxis (1986) 0.75
[Immunoscintigraphy. Development, current status and prospects]. Nuklearmedizin (1986) 0.75
[Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis]. Nuklearmedizin (1986) 0.75
[The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. Chirurg (2014) 0.75
[99mTc uptake and TSH receptor autoantibodies--comparative study in Basedow's disease and other thyroid diseases]. Nuklearmedizin (1985) 0.75